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ABSTRACT
Cancer therapy can result in significant bone loss and
increased risk of fragility fracture. Chemotherapy,
aromatase inhibitors, and gonadotropin-releasing
hormone analogues contribute to increases in the rate
of bone remodelling and reduce bone mineral den-
sity. Patients with prostate cancer on androgen dep-
rivation therapy experience an increase in the risk of
fracture. New research has demonstrated the key role
played by bisphosphonates in preventing declines in
bone density and increases in bone remodelling.
Novel antiresorptive agents targeting receptor acti-
vator of nuclear factor kB ligand have great poten-
tial in skeletal protection and prevention of bone loss
related to cancer therapy. Early assessment of skel-
etal health, followed by initiation of calcium,
vitamin D, and an exercise program are valuable in
the prevention and treatment of osteoporosis. In ad-
dition, individuals at increased risk for fracture should
be offered antiresorptive therapy. Early data have
demonstrated that bisphosphonates are able to pre-
vent the bone loss and increased bone remodelling
associated with cancer therapy, including aromatase
inhibition and androgen deprivation therapy. The
present paper reviews the new research and advances
in the management of bone loss associated with both
cancer therapy and estrogen deficiency in the post-
menopausal female.
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1. INTRODUCTION
Osteoporosis is characterized by a decline in bone
mineral density (BMD) and an associated deteriora-
tion of bone microarchitecture, resulting in increased
bone fragility and higher fracture risk 1. Osteoporotic
fractures result in increased morbidity and mortality,
with men experiencing higher mortality rates follow-
ing a hip fracture (close to 40% within the first year
of the fracture). Oncology patients are at an increased
risk of developing osteoporosis because of the ef-
fects of chemotherapy and radiotherapy. Hormonal
and non-hormonal treatment options can both also
result in hypogonadism, which can further contrib-
ute to progressive bone loss.
2. DISCUSSION
2.1 Aromatase Inhibitors, Gonadotropin-Releasing
Hormone Analogues, and Tamoxifen
In premenopausal women with breast cancer, ova-
rian ablation therapy can be associated with a rate of
bone loss as high as 13% within 12 months of treat-
ment 2. Gonadotropin-releasing hormone (GnRH) ana-
logues result in downregulation of GnRH receptors and
ovarian insufficiency within 6 months of therapy 3.
Dramatic decreases in bone density have been ob-
served in patients treated with goserelin as compared
with patients treated with cyclophosphamide, meth-
otrexate, and 5-fluorouracil (CMF) adjuvant chemo-
therapy 4. In goserelin-treated patients, BMD at the
lumbar spine decreased by 10.5%, as compared with
6.5% in CMF-treated patients (p < 0.001) 4. The CMF
patients remained estrogen-deficient and had ongo-
ing bone loss, whereas patients in the group treated
with goserelin demonstrated bone density recovery
1 year after therapy ended 5.
The aromatase inhibitors (AIs) block conversion
of androgens to estrogen and can also contribute to
bone loss 6. As a steroidal AI, exemestane has a struc-
ture similar to androstenedione and competitively
binds with aromatase. The nonsteroidal AIs anastro-
zole and letrozole reversibly inhibit the cytochrome
P450 moiety of aromatase. All three of these agents
have been approved for adjuvant treatment of breast
cancer. The major metabolite of exemestane,
17-hydroexemestane, has androgenic effects, and the
steroidal and nonsteroidal AIs may differ with respect
to their effects on bone loss and fracture. These po-
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tential differences have not been evident in clinical
trials completed to date.
All three AIs have been associated with increases
in markers of bone resorption and bone formation,
and no statistically significant differences have been
noted between the three agents 7–9. All three appear
to increase the rate of bone turnover and thus may be
associated with an increased risk of fracture 7–9. The
clinical trials completed to date have been small in
size, and the effect of AIs on fracture risk is not yet
clear, partly because in the trials completed to date,
the AIs have been compared to tamoxifen. Tamoxi-
fen exerts estrogen agonistic effects at the skeletal
level and can reduce the rate of bone remodelling
and provide skeletal protection. Thus it is not the ideal
standard against which to measure the skeletal ef-
fects of AIs.
In postmenopausal women, tamoxifen has been
shown to preserve bone density and to reduce the
rate of fracture 10–12. In premenopausal women,
tamoxifen is associated with bone loss at the spine
and hip because its effects on the skeleton are not as
potent as those of estrogen. Tamoxifen is thus acting
as a bone antagonist as it competes with the more
potent bone agonist 17b-estradiol for the estrogen
receptor in the premenopausal female. Small reduc-
tions in bone density at the lumbar spine were noted
over 3 years in premenopausal women treated with
tamoxifen as compared with women receiving pla-
cebo 11. In postmenopausal women, tamoxifen was
associated with increases in bone density of 1.17%
at the lumbar spine and 1.71% at the hip (p < 0.001);
the placebo group showed stable bone density 11. In
a primary prevention breast cancer study 13, 5 years
of tamoxifen therapy were associated with a 32%
reduction in osteoporotic fracture [95% confidence
interval (CI) = 0.51 to 0.92].
The Arimidex, Tamoxifen, Alone or in Combi-
nation (ATAC) and the Breast International Group (BIG)
trials 14,15 confirmed that adjuvant therapy with
anastrozole or letrozole was superior to tamoxifen
therapy with respect to breast cancer outcome. Eastell
and colleagues 8 concluded that anastrozole is asso-
ciated with significant BMD loss and a small increase
in bone turnover, but that tamoxifen or a combina-
tion of anastrozole and tamoxifen is associated with
increased BMD and decreased remodelling. For
anastrozole, significant loss of BMD at the lumbar spine
and hip was noted at both year 1 and year 2; with
tamoxifen, significant gains occurred at the lumbar
spine and the hip at year 1 and year 2 8. An inverse
correlation was seen between the baseline estradiol
level and BMD change: a lower baseline estradiol level
was predictive of greater BMD losses.
The ATAC trial included 9366 patients treated for
5 years. In that study, the bone resorption marker
urinary N-telopeptide of type 1 collagen (NTX) was
measured, as was the resorption marker serum C-telo-
peptide of type 1 collagen (CTX) and the formation
markers procollagen type 1 N-propeptide (P1NP) and
serum bone-specific alkaline phosphatase (bone ALP).
Patients receiving anastrozole showed increases in
bone turnover markers; patients receiving tamoxifen
tended to show decreases. At 1 year, the resorption
markers CTX and NTX increased by 26% and 15% re-
spectively (95% CI: 3% to 25%) in the anastrozole
arm. The formation markers P1NP and bone ALP in-
creased by 18% and 20% respectively (95% CI: 14%
to 25%). Tamoxifen, however, was associated with
decreases in bone resorption: CTX decreased by 56%
and NTX, by 52% (95% CI: –62% to –33%); P1NP de-
creased by 72% and bone ALP, by 16% (95% CI: –24%
to –11%). The combination of anastrozole plus
tamoxifen was comparable to tamoxifen alone with
respect to changes in bone markers. Anastrozole treat-
ment for 2 years was associated with bone loss at the
hip and spine and with increases in bone turnover 8.
The ATAC study demonstrated that the low levels
of estrogen present in postmenopausal women are
important in preserving bone density and regulating
bone turnover. The effects of anastrozole were most
notable within the first 4 years after menopause, a
period associated with a rapid rate of bone loss.
Tamoxifen was associated with skeletal protection
and resulted in preservation of bone density and a
decrease in bone turnover. However, tamoxifen in
combination with anastrozole was less effective in
improving disease-free survival than was anastrozole
alone. The combination is therefore not recommended
in the management of postmenopausal women with
breast cancer.
The ATAC trial found that anastrozole had a safer
profile than tamoxifen with respect to endometrial
cancer, cerebrovascular events, and venous throm-
boembolic events 14. However, as compared with
tamoxifen, anastrozole was associated with an increase
in the overall fracture rate (11% vs. 7.7%, p <
0.0001) 16. In the BIG 1-98 trial, a higher incidence of
clinical fractures was noted in the letrozole group as
compared with the tamoxifen group (5.7% vs. 4%,
p < 0.001) 15. However, these trials make it difficult
to confirm the effects of AIs on fracture, because the
control group was treated with tamoxifen, which has
protective skeletal effects and preserves bone density.
The effect of tamoxifen on fracture has not yet
been confirmed. How an agent affects vertebral frac-
ture is best evaluated by serial X-ray of the spine.
Unfortunately, the large trials conducted to date have
not included serial spinal radiographs as part of the
clinical assessment, and therefore the effect of AIs on
vertebral fracture is difficult to define.
The use of AIs after tamoxifen therapy has been
evaluated. Exemestane was studied in 4742 post-
menopausal women with breast cancer who had pre-
viously received 2–3 years of tamoxifen therapy 17.
Patients were randomized to switch to exemestane
for the remainder of the 5-year treatment program or
to complete a full 5 years on tamoxifen. AfterBONE LOSS RELATED TO CANCER TREATMENT
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30 months of follow-up, a higher, but not statistically
significant, clinical fracture rate was noted in the
exemestane group as compared with the tamoxifen
group (3.1% vs. 2.3%, p = 0.08). A new diagnosis of
osteoporosis was more common in the exemestane
group (7.4% vs. 5.7%, p = 0.05) 17.
Anastrozole after tamoxifen has also been asso-
ciated with a greater number of clinical fractures than
has tamoxifen alone (2% vs. 1%, p < 0.05) 18. But
the effect of the AI on fracture is difficult to interpret,
because tamoxifen, being an estrogen agonist in the
postmenopausal female, may have reduced the risk
of fracture. The study included premenopausal and
postmenopausal women alike, and did not obtain
spinal radiographs. These limitations make it diffi-
cult to confirm the effect of the AI on the incidence of
fracture.
In a 2-year randomized control trial 19, exemes-
tane was compared to placebo in postmenopausal
women with early breast cancer. Assessments of spine
and hip by dual X-ray absorptiometry were completed
on an annual basis. After 1 year, the exemestane group
showed declines in bone density at the lumbar spine
(2.2%) and the hip (2.7%). The placebo group also
experienced declines in bone density (1.8% at the
spine, 1.5% at the hip). There was no significant dif-
ference between the two groups at the spine; the dif-
ference at the hip was statistically significant at p =
0.023 19. Exemestane-treated patients demonstrated
increases in bone remodelling, with an increase of
44% in P1NP and 35% in CTX. The increased rates of
bone turnover were consistent with the data obtained
from other clinical trials.
Eastell and colleagues evaluated risk factors for
fracture in the ATAC study 8. Older age was associated
with a higher risk of fracture. Low bone density
T scores of less than –2.5 were also associated with a
higher risk of fracture than were bone density T scores
greater than –1.5. These authors also noted that use
of a statin was associated with a lower risk of fracture.
Androgen deprivation therapy has been evalu-
ated with respect to its effects on bone loss and frac-
ture. Gonadotropin-releasing hormone agonists
reduce serum concentrations of testosterone by more
than 95% 20. That decline is associated with dramatic
reductions in bone density of about 4%–10% within
the first year of treatment 21. An increased risk of fra-
gility fractures was documented retrospectively with
androgen deprivation therapy in men with prostate
cancer 22–24. In a retrospective review of 50,613 men
who received a diagnosis of prostate cancer, 19.4%
of those who received androgen deprivation therapy
had a fracture, as compared with 12.6% of those who
did not receive such therapy (p < 0.001) 16. Duration
of treatment was an independent predictor for frac-
ture risk. Men who received 9 or more doses of GnRH
agonists in the year after diagnosis and men who
underwent orchiectomy both had a relative risk of
fracture of 1.45 (95% CI: 1.36 to 1.56) 16.
Bicalutamide, an approved agent for prostate can-
cer, is a nonsteroidal anti-androgen. It competitively
binds to the androgen receptors in target tissues, in-
hibiting the effects of androgen. It can increase serum
concentrations of estradiol 25. As compared with GnRH
analogues, bicalutamide has been shown to increase
BMD 26.
2.2 Prevention and Treatment of Osteoporosis
In addition to adequate calcium, vitamin D, and ex-
ercise, options for the prevention and treatment of
osteoporosis include antiresorptive and anabolic
agents.
Antiresorptive (anticatabolic) agents inhibit os-
teoclast activity and reduce bone turnover 2, with the
various agents having different mechanisms of ac-
tion. Bisphosphonates reduce the rate of bone turn-
over, providing a longer time for bone to mineralize.
Bisphosphonate therapy is thus associated with mod-
est increases in BMD. Estrogen acts through the estro-
gen receptors on both osteoblasts and osteoclasts, and
results in suppression of receptor activator of nuclear
factor kB ligand (RANKL)–induced osteoclast differ-
entiation, thereby decreasing bone remodelling 3.
Raloxifene, a selective estrogen receptor modulator
(SERM), can bind to estrogen receptors, with tissue-
specific agonist or antagonist effects. Raloxifene de-
creases bone remodelling, in addition to its other
extraskeletal effects. Osteoclastic bone resorption is
also inhibited by calcitonin acting on calcitonin
receptors.
The antiresorptive agents mentioned above are
effective in reducing fracture risk by approximately
30%–50% in the postmenopausal female population.
However, fractures still occur, and more effective
options are desirable, particularly for severe disease
states. Anabolic therapy can make major improve-
ments in the quality and quantity of bone, and ana-
bolic agents are a welcome addition to the
antiresorptive options currently available.
Anabolic therapy can increase the production of
bone matrix by enhancing osteoblastic function. The
resulting reduction in risk of fracture is approximately
65% over 18 months in the postmenopausal female
with osteoporosis 27. The currently approved anabolic
agent is teriparatide. Strontium ranelate has been
shown to have antiresorptive properties; it may also
have anabolic properties. This agent is expected to
be approved in Canada for the treatment of postmeno-
pausal osteoporosis before the end of 2008.
2.2.1 Calcium and Vitamin D
The Scientific Advisory Council of Osteoporosis
Society of Canada recommends 28
• 1500 mg elemental calcium daily and 800 IU
vitamin D daily for women and men 50 years of
age and older.KHAN and KHAN
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• 400 IU vitamin D daily and 1000 mg elemental
calcium daily for all adults under 50 years of age.
The effectiveness of calcium and vitamin D in
preventing hip fracture was evaluated in the Women’s
Health Initiative (WHI) trial, which involved 36,282
postmenopausal women who daily received either
1000 mg calcium and 400 IU vitamin D, or a pla-
cebo, for an average of 7 years 29. Patients were al-
lowed to take additional daily supplements of up to
1000 mg calcium and 600 IU vitamin D. Personal use
of bisphosphonates, calcitonin, SERMs, and estrogen
therapy was also permitted, and approximately 38%
of subjects took more than 1200 mg elemental cal-
cium daily. In the WHI, the calcium and vitamin D
study arm overlapped with the hormone replacement
therapy (HRT) arm, and thus approximately 51% of
patients were receiving estrogen.
Treatment compliance was poor: by the end of
the study, only 59% of patients were taking more than
80% of their medication. As compared with the pa-
tients taking placebo, the patients taking 1000 mg
calcium and 400 IU vitamin D daily showed a 1.06%
increase in hip BMD (p < 0.01). In the treatment-com-
pliant group, the hazard ratio for hip fracture was 0.71
(95% CI: 0.52 to 0.97), representing a statistically sig-
nificant 29% reduction in hip fracture risk in the in-
dividuals taking more than 80% of their calcium and
vitamin D supplements. Estrogen use was associated
with a 42% reduction in hip fracture risk. A small,
but significant, 17% increase in risk of renal stones
was noted in the treatment group as compared with
the placebo group, with a hazard ratio of 1.17 (95%
CI: 1.02 to 1.34) 29. Clinicians must therefore ensure
that patients are not inadvertently taking excessive
calcium supplements and that their urinary calcium
excretion is normal, particularly when a history of
renal stone formation is present.
Vitamin D inadequacy was also noted in the WHI
study and may have contributed to the findings. In
the nested case–control study, the mean 25-hydroxy
vitamin D level was 46 nmol/L in patients who sus-
tained hip fractures as compared with 48.4 nmol/L
in control subjects 29. Vitamin D supplementation of
more than 600 IU daily may have reduced the frac-
ture risk, as has been demonstrated in other clinical
trials. Ensuring adequate vitamin D supplementation
is a key component of therapy in the prevention and
treatment of osteoporosis.
2.2.2 Antiresorptive Therapy
SERMs: The SERM class of agents demonstrates tissue-
specific estrogen-agonistic or estrogen-antagonistic
effects 30. In the Multiple Outcomes of Raloxifene
Evaluation trial, patients treated with either 60 mg or
120 mg raloxifene daily for 4 years demonstrated a
36% and 43% reduction in vertebral fracture risk re-
spectively 31. However, no significant effect on the
risk of non-vertebral fractures was noted 31. The lat-
ter finding may have been the result of multiple fac-
tors, including the very low incidence of non-vertebral
fractures seen in the placebo arm of this trial, as com-
pared with incidences seen in the randomized clini-
cal trials for other antiresorptives.
In the Study of Tamoxifen and Raloxifene, in-
volving 19,747 postmenopausal women with in-
creased risk of breast cancer, 60 mg raloxifene daily
demonstrated breast cancer risk reduction effects
equivalent to 20 mg tamoxifen daily over 5 years 32.
(Both drugs reduce the risk of breast cancer by ap-
proximately 50%.) Raloxifene was associated with a
better overall safety profile than tamoxifen was, with
36% fewer uterine cancers and 29% fewer deep vein
thromboses 32.
Bisphosphonates: Nitrogen-containing bisphos-
phonates (alendronate, risedronate, zoledronic acid)
demonstrate antiresorptive effects by binding to the
calcium hydroxylapatite crystal at sites of bone re-
sorption where the bone matrix is exposed 33. The
bisphosphonate is buried under the newly formed
bone, where it lies inert and has no skeletal effects.
During bone resorption, the drug is released from the
bone matrix and is ingested by osteoclasts; it inhibits
farnesyl diphosphate synthase (FDPS), a key enzyme
in the cholesterol synthesis pathway involved in post-
translational modification of important signalling
molecules (Ras, Rac, Rho, and Rab). The FDPS inhi-
bition disrupts several pathways involved in cyto-
skeletal organization, cell survival, and cell
proliferation, leading to osteoclast deactivation and
apoptosis 34. The result is reduced bone turnover and
enhanced bone mineralization because of the ex-
tended time available for mineral accumulation. With
the normalization of bone remodelling to premeno-
pausal levels, overall bone strength is improved 34,35.
Alendronate: Alendronate effectively reduces the risk
of vertebral fractures in postmenopausal women with
and without baseline vertebral fractures, as has been
demonstrated in the Fracture Intervention Trial
(FIT) 36–38. Several trials have shown that alendronate
use reduces bone resorption and improves BMD 38,39.
In early postmenopausal women, alendronate for
5 years inhibited bone loss at the spine, hip, and total
body 37. In a separate study involving women below
60 years of age, 5 mg alendronate daily resulted in a
3.5% increase in BMD at the lumbar spine, together
with a 1.9% increase at the hip (p < 0.001 as com-
pared with baseline at both sites) 39. It is worth not-
ing that the FIT Long-term Extension study reported
that increases in BMD continued at the lumbar spine
and hip through 10 years of treatment, with an asso-
ciated fracture risk reduction 38. Bone biopsies per-
formed in patients following 10 years of alendronate
treatment revealed double fluorescent tetracycline
label in all biopsy samples, indicating ongoing bone
remodelling and an absence of “frozen” bone 38.BONE LOSS RELATED TO CANCER TREATMENT
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Those data provides reassurance that long-term
alendronate therapy can safely reduce vertebral and
non-vertebral fractures.
Bisphosphonates may prevent bone loss associ-
ated with GnRH-induced hypogonadism, as was first
evaluated with etidronate 40. Clinical trials are cur-
rently evaluating the use of alendronate or risedronate
in the prevention of bone loss in association with AIs.
Risedronate: Risedronate maintains bone mass and
preserves bone microarchitecture 41. A number of stud-
ies in postmenopausal women have shown that
risedronate significantly reduces the risk of vertebral
and non-vertebral fractures alike 42–44. Analysis of data
from the Vertebral Efficacy with Risedronate Therapy
trials indicated that 5 mg risedronate daily reduced
the incidence of new fractures within 6 months of start-
ing therapy and significantly lowered the risk of new
vertebral fractures within 1 year 42–44. This reduction
in fracture risk was maintained for up to 7 years of
treatment 45. Risedronate effectively reduced the risk
of hip fractures in a study evaluating 9331 elderly
women at high risk of fracture 41.
Risedronate has been shown to effectively reduce
the risk of non-vertebral fractures after 3 years of treat-
ment 46. Another study, involving early postmeno-
pausal women, demonstrated that, as compared with
placebo, 5 mg risedronate daily increased BMD at the
lumbar spine by more than 5% during 2 years of treat-
ment (p < 0.05 as compared with both baseline and
placebo) 47. Other studies have confirmed those find-
ings, showing that risedronate prevents bone loss and
preserves trabecular architecture in early postmeno-
pausal women 48. In addition, key clinical trials have
shown that reductions in vertebral fracture risk with
risedronate are independent of increases in BMD 41.
The Study of Anastrozole with the Bisphospho-
nate Risedronate evaluated the effects of risedronate
on BMD and bone turnover in postmenopausal women
using anastrozole as adjuvant therapy for hormone
receptor–positive early breast cancer 49. The pre-
planned analysis of markers of bone turnover after
6 months of therapy were presented in June 2007 49.
Patients were stratified according to baseline frac-
ture risk by lumbar spine and hip T scores, with higher
risk defined as including patients with a T score of
less than –2 or a history of fracture, or both. “Moder-
ate risk” included patients with a T score of less than
–1, but greater than or equal to –2. “Low risk” in-
cluded patients with a T score of –1 or better. High-
risk patients received open-label anastrozole plus
risedronate 35 mg once weekly. Moderate-risk pa-
tients were randomized in a double-blind manner to
receive anastrozole plus risedronate or placebo. Low-
risk patients received open-label anastrozole only. All
patients were given calcium and vitamin D. Low-risk
patients demonstrated a significant increase in serum
CTX (p = 0.05), but no significant change in P1NP or
bone ALP. Significant decreases in all bone markers
were noted for the high-risk patients (p < 0.0001). In
the moderate-risk group, all markers significantly
declined in patients receiving anastrozole plus
risedronate as compared with patients receiving
anastrozole plus placebo (p < 0.0001). Risedronate
was able to reduce bone turnover in anastrozole-
treated postmenopausal women with hormone recep-
tor–positive early breast cancer and a pre-existing
moderate or higher risk of fracture 49.
Zoledronic Acid: Zoledronic acid is the most potent
bisphosphonate currently available 50,51. It contains
two nitrogen atoms in the R2 side chain, and the in-
travenous administration of 4-mg doses has been
approved for the prevention and treatment of meta-
static bone disease and hypercalcemia of malignancy.
Zoledronic acid 5 mg has been approved in Canada
as a treatment for Paget disease.
In a double-blind placebo-controlled dose-rang-
ing trial involving 351 postmenopausal women with
low BMD, significant reductions in markers of bone
resorption were noted, together with improvements
in BMD, in all treatment groups over placebo 52. In ad-
dition, the study noted that zoledronic acid 4 mg an-
nually achieved reductions in bone turnover
comparable to those seen with daily oral bisphospho-
nate therapy 52.
The phase III randomized controlled Health Out-
comes and Reduced Incidence with Zoledronic Acid
Once Yearly (HORIZON) pivotal fracture trial (PFT)
evaluated the effects of zoledronic acid 5 mg annu-
ally on fracture incidence in men and women 50 years
of age or older who had already sustained a low-
trauma hip fracture 53. Data from that trial demon-
strated that zoledronic acid reduced the 3-year risk
of vertebral fractures by 70% over placebo (relative
risk: 0.30; 95% CI: 0.24 to 0.38). The 3-year fracture
risk for hip fractures was reduced by 41% in the
zoledronic acid group over placebo. Increases in BMD
were significantly higher and height loss was lower
in the zoledronic acid group 53.
In another study, 301 patients receiving adjuvant
letrozole were randomized to upfront or delayed
zoledronic acid given intravenously in doses of 4 mg
every 6 months 54. Zoledronic acid was administered
when the lumbar spine or total hip T score dropped
below –2 or in the presence of a non-traumatic frac-
ture. At 12 months, lumbar spine BMD was 4.4%
higher in the upfront group than in the delayed start
group. Bone resorption marker was also 15% lower
in the upfront group. Zoledronic acid has been ap-
proved for the prevention of osteoporosis in the post-
menopausal female population. Further evaluation of
this valuable agent in preventing bone loss induced
by cancer treatment is planned.
Bisphosphonate Advantages and Disadvantages: A
major advantage of oral bisphosphonate therapy is
ease of administration and an excellent tolerability
profile. The side effects most commonly associatedKHAN and KHAN
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with such therapy are abdominal pain and dysphagia.
However, alendronate and risedronate have both dem-
onstrated upper gastrointestinal side effects compa-
rable to placebo in the randomized controlled trials
conducted to date 55. Intravenous administration of
bisphosphonates provides a number of advantages,
including less frequent dosing and less potential for
gastrointestinal side effects as compared with oral
bisphosphonates.
Recently, reports of mandibular or maxillary
osteonecrosis as a potential rare complication of bis-
phosphonate use have been published 56. Osteo-
necrosis of the jaw (ONJ) is an avascular bone necrosis
that may occur in patients at risk for this condition.
Most of the reports have been associated with fre-
quent high-dose administration of intravenous pami-
dronate or zoledronic acid in oncology patients with
a history of breast cancer or myeloma. Many of these
patients have been on concomitant chemotherapy or
radiotherapy (or both), which are risk factors for avas-
cular bone necrosis. The condition has been most
commonly reported in high-risk individuals follow-
ing dental surgery such as dental extraction 57. The
condition has seldom been reported with alendronate
and risedronate use 56. It is important to note that ONJ
has not been seen in any of the clinical trials con-
ducted to date, which represent prospective data ob-
tained in more than 100,000 patients treated with
aminobisphosphonates for an average of 3 years. All
published cases have been anecdotal reports. In a ret-
rospective chart review by the M.D. Anderson Can-
cer Center of 4000 cancer patients treated with
zoledronic acid, pamidronate, or both, ONJ was iden-
tified in 0.825% of the patient population 58. The
HORIZON PFT trial found that the incidence of ONJ was
similar in the treatment and placebo groups, with
1 case occurring in each group. The cases were vali-
dated by an adjudication committee.
Canadian guidelines regarding the diagnosis, pre-
vention, and management of ONJ are expected to be
published in early 2008 by a Canadian multidisci-
plinary task force on ONJ. Current international guide-
lines recognize ONJ as a very rare condition limited
mostly to the oncology population receiving high-
dose intravenous bisphosphonates. Prospective data
in the oncology and non-oncology population are
needed to better understand the underlying pathophysi-
ology of ONJ so that appropriate decisions can be made
about prevention, diagnosis, and management.
Administration of potent bisphosphonates has
been shown to provide a number of advantages in
patients with metastatic disease, such as the ability
to effectively control hypercalcemia and to stabilize
bone lesions while bypassing the gastrointestinal tract.
Thus, intravenous bisphosphonates are of tremendous
value in the management of skeletal complications
in patients with malignancy, and they are an impor-
tant component of therapy in those patients. The ben-
efits of intravenous bisphosphonates far outweigh the
risks of developing ONJ. Further prospective data are
needed for the true incidence and pathophysiology
of ONJ to be understood. The exact relationship be-
tween ONJ and the use of bisphosphonates also needs
to be clarified. It should also be noted that the annual
dose of intravenous bisphosphonates used in os-
teoporosis is significantly lower than that used in
cancer patients.
Bisphosphonates are a valuable treatment option
for postmenopausal osteoporosis as well as for ste-
roid-induced bone loss. These agents may also be
effective in preventing bone loss associated with can-
cer therapy; however, they have not yet been ap-
proved specifically for that indication.
HRT: Hypogonadism may be the result of cancer
therapy in non-hormone dependent tumours such as
lymphoma. In those circumstances, hypogonadism
will be associated with progressive bone loss and is
not an intended effect of cancer treatment. Data re-
garding estrogen replacement in the postmenopausal
female has confirmed significant improvements in
BMD, reductions in the rate of bone turnover, and re-
ductions in the risk of vertebral and non-vertebral
fracture.
Estrogen therapy has significant antiresorptive
effects. Specifically, it enhances the osteoblastic pro-
duction of osteoprotegerin, which has anti-osteoclas-
tic properties because of its ability to bind to RANKL
and subsequently to block the RANKL/RANK interac-
tion required for osteoclast recruitment and activa-
tion 59,60. In the WHI, a primary prevention trial, the
combined estrogen plus progesterone arm demon-
strated an increase in total hip BMD, together with a
34% reduction in hip and vertebral fractures and a
24% reduction in total osteoporotic fractures 61. The
estrogen-only arm presented similar results, with a
30%–39% reduction in fracture rates 62. This trial
therefore confirmed the antifracture effects of HRT
suggested by previous clinical trials 63,64. In early
postmenopausal women, combined estrogen–proges-
terone therapy resulted in increases in BMD of 2%–
3% at the hip and spine over 2 years of therapy 63. A
decline in the markers of bone turnover in response
to HRT was also seen in early postmenopausal
women 64. The combined estrogen and progesterone
arm experienced a 26% increased risk of breast can-
cer and a 29% increased risk of cardiac events,
prompting the early termination of this treatment
group after 5.2 years of follow-up 65. The estrogen-
alone arm was also terminated prematurely because
of a 41% increased risk of stroke and a doubling of
the risk of thromboembolic disease 62. Because the
risks of HRT are significant and appear to outweigh
the benefits, HRT is considered a treatment option for
select patients unsuited to standard first-line
antiresorptive therapies 66.
RANKL Inhibitors: Denosumab is a fully human
monoclonal antibody to RANKL; it binds to humanBONE LOSS RELATED TO CANCER TREATMENT
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RANKL, thus preventing osteoclast activation and sub-
sequently reducing bone resorption. A phase II study
reported by McClung et al. demonstrated that
denosumab was well-tolerated and had an effect on
bone turnover similar to that of alendronate 67. As
compared with patients who received placebo, pa-
tients treated with denosumab experienced signifi-
cantly increased BMD. Subcutaneous administration
of the drug in doses of either 30 mg every 3 months,
or 60 mg every 6 months, resulted in sustained de-
creases in urinary N-telopeptide excretion 67.
In addition, denosumab has been shown to effec-
tively reduce bone turnover in patients with meta-
static bone disease, with effects comparable to those
of intravenous pamidronate 68. This agent is currently
being evaluated further in oncology patients with
metastatic skeletal disease and in patients with post-
menopausal osteoporosis. It is expected to become a
valuable additional option in the management of those
conditions.
2.2.3 Anabolic Agents
Until recently, postmenopausal osteoporosis treat-
ment was limited to antiresorptive therapies. How-
ever, the availability of anabolic agents—namely,
parathyroid hormone (PTH) and strontium ranelate—
represent a major advance. Anabolic agents result in
major improvements in the quality and the quantity
of bone, significantly increasing bone strength.
PTH—Teriparatide and Full-Length PTH: Teripara-
tide, a 34-amino acid recombinant fragment of the 84–
amino acid human PTH, is administered subcutaneously
in doses of 20 mg daily for 18 months. Although ex-
posure to continuously elevated PTH levels is associ-
ated with bone loss, intermittent pulse therapy with
PTH preferentially stimulates osteoblast activity and is
associated with increases in BMD 69. Teriparatide pro-
motes the differentiation of pre-osteoblasts into bone-
forming osteoblasts 70, resulting in a net increase in
both the number and activity of bone-forming cells 69.
Several clinical trials have noted impressive effects
of teriparatide on BMD and fracture risk 27,71–75.
In a randomized controlled trial involving post-
menopausal women with fragility fractures,
teriparatide 20 mg daily over 21 months led to a 9%
increase in lumbar spine BMD and improved BMD at the
femoral neck and whole body 27. Risks for vertebral
and non-vertebral fractures were reduced by 65% and
53% respectively 27. Evidence for the anabolic effects
of teriparatide on bone microarchitecture has been
found in bone biopsies of patients treated with teri-
paratide. These show dramatic increases in the thick-
ness, density, and number of trabeculae and increases
in cortical thickness and bone size 71. A reduction in
back pain has also been noted with teriparatide use.
The full-length PTH molecule (1-84) has been as-
sessed in the Treatment of Osteoporosis trial 72. That
2-year study involved 2532 postmenopausal osteopor-
otic women who were randomized to receive 100 mg
PTH (1-84) or placebo. The PTH was found to reduce
the incidence of new vertebral fractures by 66%.
Teriparatide is well-tolerated; however, minor
adverse events such as nausea, headaches, and tran-
sient mild hypercalcemia have been noted 70. Prelimi-
nary studies in rats, in which the animals received
near-lifelong exposure to high doses of teriparatide
(5 mg/kg or more daily), found a dose- and duration-
dependent relationship between teriparatide and the
development of osteosarcoma 76. However, such
doses are much higher than the 20 mg daily dose (ap-
proximately 0.28 mg/kg daily) used in humans, and
osteosarcoma has not been seen in humans or in stud-
ies with monkeys. Furthermore, it is important to note
that osteosarcoma does not occur with increased fre-
quency in individuals with primary hyperparathyroid-
ism. To date, 300,000 people have been treated with
teriparatide, and 1 case of osteosarcoma has occurred,
which is comparable to the background incidence of
osteosarcoma of 1 in 250,000.
Teriparatide is contraindicated in individuals who
have had metastatic skeletal disease or who have a
history of skeletal radiation. It is also contraindicated
in patients with renal insufficiency, hypercalcemia,
hypercalciuria, or elevated ALP that has not yet been
evaluated. Because osteosarcoma is more common
in individuals with Paget disease, teriparatide is con-
traindicated in those patients.
Combination therapies have included teriparatide
in combination with HRT or with bisphosphonates 73,74.
Data suggest that pretreatment with alendronate may
blunt the anabolic effects of PTH therapy 77. Long-term
fracture risk studies are required to determine if com-
bination therapy is of value.
Strontium Ranelate: Strontium ranelate has demon-
strated antiresorptive effects and also appears to have
anabolic properties. It has not been associated with
an increased risk of osteosarcoma. It is incorporated
into bone and accumulates in the skeleton because of
its physical and chemical similarities to calcium 78.
Strontium ranelate provides skeletal benefits be-
cause it stimulates replication of pre-osteoblasts and
synthesis of bone matrix; it also prevents bone re-
sorption by inhibiting osteoclasts 79–83. In a study in-
volving ovariectomized rats, strontium ranelate
prevented bone loss by reducing bone resorption and
enhancing bone formation 84. A phase III trial involv-
ing 1649 postmenopausal women demonstrated a
49% reduction in new vertebral fractures at 1 year in
subjects administered strontium ranelate 2 g daily as
compared with those receiving placebo 85. A 16%
reduction in non-vertebral fractures in the strontium
ranelate group was also noted 86. Subjects at high risk
of fracture (74 years of age or older with a femoral
neck BMD T score of –3 or lower) demonstrated an
even greater reduction in risk of hip fracture (36%,
p = 0.046) 58. Side effects associated with strontiumKHAN and KHAN
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ranelate have been limited to nausea and diarrhea
during the first few months of therapy 80. Current
guidelines recommend that intervention be based on
the presence of low BMD and planned cancer treatment.
2.3 Available Guidelines
International guidelines have been published provid-
ing recommendations for skeletal protection in on-
cology patients, including guidelines from the
American Society for Clinical Oncology. A 2007
consensus statement published by the Belgian Bone
Club provides recommendations for the management
of bone loss induced by cancer treatment in early
breast and prostate cancer 87. Their recommendations
include assessment of fracture risk and bone density
testing by dual X-ray absorptiometry for all women
beginning medical castration therapy or aromatase
therapy. All men beginning androgen deprivation
therapy should similarly be evaluated for risk of os-
teoporosis. Monitoring of BMD every 1–2 years for
osteoporotic and osteopenic patients is recommended.
In individuals with a normal baseline BMD, that as-
sessment is recommended be repeated every 2–
5 years, depending on the presence of other risk
factors. Lifestyle modification with appropriate cal-
cium and vitamin D supplementation is also recom-
mended. Further evaluation to exclude secondary
causes of osteoporosis such as vitamin D deficiency,
hyperparathyroidism, or hyperthyroidism is recom-
mended to ensure that no other factors are contribut-
ing to bone loss apart from androgen deprivation
therapy or induction of hypogonadism.
Bisphosphonate therapy is recommended for os-
teoporotic individuals with a T score of –2.5 or lower,
or a history of a fragility fracture. Bisphosphonates
are also recommended for individuals who have im-
portant risk factors for fracture and osteopenia with
a T score between –1 and –2.5. In the latter case, the
recommendations suggest zoledronic acid 4 mg every
6 months for patients receiving AIs and zoledronic
acid 4 mg annually or alendronate weekly for patients
receiving androgen deprivation therapy.
Ongoing clinical trials evaluating the skeletal
protective effects of bisphosphonates will provide
further refinement of the existing recommendations.
3. SUMMARY
Osteoporotic fractures result in significant morbidity
and increased mortality rates. Cancer treatment can
dramatically reduce bone density and increase the rate
of bone turnover and the risk of fragility fracture.
The importance of both quantity and quality of bone
in determining bone strength and fracture risk has
been recognized. Bisphosphonates are being evalu-
ated for their skeletal protective effects, and they offer
great promise in the prevention of fragility fracture
for patients receiving cancer treatment. Clinical re-
search is also evaluating RANKL inhibitors, and other
antiresorptive options and anabolic therapies are ex-
pected to possibly play a future role in the preven-
tion of fracture in the patient with cancer. Early
diagnosis and treatment of osteoporosis will contrib-
ute to improved health and wellbeing for the patient
receiving cancer treatment.
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